datopotamab deruxtecan

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
  While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…
  biospace · 16d ago
• ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
  If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
  biospace · 18d ago
• Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
  Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patien…
  fiercebiotech · 18d ago
• Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
  With Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.
  biospace · 22d ago
• Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
  Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.
  biopharma_dive · 22d ago
• Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
  After keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before quietly scrubbing the ev…
  fiercebiotech · 22d ago
• AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
  AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.
  fiercebiotech · 25d ago
• Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
  With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.
  biospace · 1mo ago
• On second try, Acadia drug gets nod from European regulators
  The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.
  biopharma_dive · 1mo ago
• At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
  Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.
  biopharma_dive · 2mo ago